Can Ranbaxy recover from its US debacle?

“We are pleased to have resolved this legacy issue with the FDA as we begin the next chapter in Ranbaxy’s history,” stated Arun Sawhney, CEO & Managing Director of India’s biggest drug-maker Ranbaxy few weeks ago. Sawhney’s announcement came on December 21, after Ranbaxy signed a consent decree with the US Food and Drugs Administration (USFDA)—the body that green lights the entry of all drugs into its markets—to resolve all pending issues that his company has with the US regulator.

Read Full Story>>